Shuttle Pharmaceuticals (NASDAQ:SHPH) CEO Anatoly Dritschilo joins Natalie Stoberman from the Proactive studio to discuss the company's progress with its Phase II clinical study of Ropidoxuridine and radiation therapy. Shuttle says it anticipates final IND application submission to the FDA in the second quarter of 2023.
Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy by maximizing the effectiveness of radiation therapy while limiting the side effects of radiation in cancer treatment.